[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.94.5. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1980

Ketoconazole Treatment of Chronic Mucocutaneous Candidiasis

Author Affiliations

From the Infectious Diseases Section, Audie L. Murphy Memorial Veterans Hospital, San Antonio, Tex (Dr Graybill); the Departments of Medicine (Dr Graybill) and Pediatrics (Dr Kniker), University of Texas Health Science Center, San Antonio; the Naval Biosciences Laboratory (Dr Levine), Oakland, Calif; and the Department of Medicine, University of Texas Southwestern Medical School, Dallas (Dr Herndon). Dr Herndon is now in private practice in Dallas.

Arch Dermatol. 1980;116(10):1137-1141. doi:10.1001/archderm.1980.01640340047014
Abstract

• Five patients received ketoconazole treatment of chronic mucocutaneous candidiasis. One also had disseminated histoplasmosis and cryptococcosis. Ketoconazole was well absorbed after an oral dose of 200 mg and produced detectable antifungal blood levels for more than eight hours after each dose. Thrush cleared in less than two weeks in all patients. Cutaneous lesions cleared slowly during several months of treatment. A patient with polymycotic infection had a rapid clearing of candidiasis, but her histoplasmosis did not respond to three weeks of treatment. Adverse drug effects were minimal. Ketoconazole is a promising new agent for treatment of chronic mucocutaneous candidiasis.

(Arch Dermatol 116:1137-1141, 1980)

×